Quick answers
- What is Olmesartan medoxomil and hydrochlorothiazide used for?
- The FDA-approved label (Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, July 14, 2026) says: “BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension […]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Olmesartan medoxomil and hydrochlorothiazide?
- The “Adverse Reactions” section of the FDA label (Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, July 14, 2026) begins: “The following adverse reactions with BENICAR HCT are described elsewhere: Hypotension in Volume- or Salt-Depleted Patients [see Warnings and Precautions (5.2)] Impaired Renal Function [see Warnings and Precautions (5.3)] Hypersensitivity Reactions [see Warnings and Precautions (5.4)] Electrolyte and Metabolic Imbalances [see Warnings and Precautions (5.5)] Acute Myopia and Secondary Angle-Closure Glaucoma [see Warnings and Precautions (5.6)] Systemic Lupus Erythematosus [see …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Olmesartan medoxomil and hydrochlorothiazide?
- The “Drug Interactions” section of the FDA label (Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, July 14, 2026) begins: “Lithium: Risk of lithium toxicity (7.2) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic and antihypotensive effects; increased risk of renal toxicity (7.3) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.4) Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose (7.5) Antidiabetic drugs: Dosage adjustment may be required (7.6) Cholestyramine and colestipol: Reduced absorption of thiazides (7.6) 7.1 Agents Increasing Serum Potassium Coadministration of BENICAR HCT with other drugs that raise serum potassium levels may result in hyperkalemia.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Olmesartan medoxomil and hydrochlorothiazide have a boxed warning?
- Yes. The FDA label for Olmesartan Medoxomil-Hydrochlorothiazide has a boxed warning (“WARNING: FETAL TOXICITY”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Olmesartan medoxomil and hydrochlorothiazide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Olmesartan medoxomil and hydrochlorothiazide been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Olmesartan medoxomil and hydrochlorothiazide?
- 20 companies list prescription products of Olmesartan medoxomil and hydrochlorothiazide in the FDA NDC Directory, including A-S Medication Solutions, Bryant Ranch Prepack and Cosette Pharmaceuticals, Inc.
What Olmesartan medoxomil and hydrochlorothiazide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension […]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. …
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (tablet, film coated, oral), Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE; it covers 3 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 43 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: FETAL TOXICITY
. Read it on the full label →
43 of 43 FDA labels for this medicine have a boxed warning.
Olmesartan medoxomil and hydrochlorothiazide boxed warning: what the label says
Quoted from the boxed warning of the FDA-approved label.
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue BENICAR HCT as soon as possible [see Warnings and Precautions (5.1)]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue BENICAR HCT as soon as possible (5.1).
Read more of this section
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1).
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. Read the full label on DailyMed →
Olmesartan medoxomil and hydrochlorothiazide side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following adverse reactions with BENICAR HCT are described elsewhere: Hypotension in Volume- or Salt-Depleted Patients [see Warnings and Precautions (5.2)] Impaired Renal Function [see Warnings and Precautions (5.3)] Hypersensitivity Reactions [see Warnings and Precautions (5.4)] Electrolyte and Metabolic Imbalances [see Warnings and Precautions (5.5)] Acute Myopia and Secondary Angle-Closure Glaucoma [see Warnings and Precautions (5.6)] Systemic Lupus Erythematosus [see …
Table from the label
| Olmesartan/HCTZ (N=247) (%) | Olmesartan (N=125) (%) | HCTZ (N=88) (%) | Placebo (N=42) (%) | |
|---|---|---|---|---|
| Nausea | 3 | 2 | 1 | 0 |
| Hyperuricemia | 4 | 0 | 2 | 2 |
| Dizziness | 9 | 1 | 8 | 2 |
| Upper Respiratory Infection | 7 | 6 | 7 | 0 |
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. This is part of the section. Read the full label on DailyMed →
Olmesartan medoxomil and hydrochlorothiazide drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Lithium: Risk of lithium toxicity (7.2) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic and antihypotensive effects; increased risk of renal toxicity (7.3) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.4) Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose (7.5) Antidiabetic drugs: Dosage adjustment may be required (7.6) Cholestyramine and colestipol: Reduced absorption of thiazides (7.6) 7.1 Agents Increasing Serum Potassium Coadministration of BENICAR HCT with other drugs that raise serum potassium levels may result in hyperkalemia.
Read more of this section
Monitor serum potassium in such patients. 7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists or hydrochlorothiazide. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors Olmesartan medoxomil In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including olmesartan medoxomil) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors. Hydrochlorothiazide In some patients the administration of a NSAID can reduce the diuretic, natriuretic, and antihypertensive effects of thiazide diuretics. Therefore, monitor blood pressure closely. 7.4 Dual Blockade of the Renin Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on BENICAR HCT and other agents that affect the RAS. Do not co-administer aliskiren with BENICAR HCT in patients with diabetes [see Contraindications (4)]. Avoid use of aliskiren with BENICAR HCT in patients with renal impairment (GFR <60 ml/min). 7.5 Colesevelam H ydrochloride Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan. Administration of olmesartan at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose [see Clinical Pharmacology (12.3)]. 7. 6 The Use of Hydrochlorothiazide with Other Drugs When administered concurrently the following drugs may interact with thiazide diuretics: Antidiabetic drugs (oral agents and insulin): Dosage adjustment of the antidiabetic drug may be required.
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. This is part of the section. Read the full label on DailyMed →
Olmesartan medoxomil and hydrochlorothiazide dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
The recommended starting dose of BENICAR HCT is 40/12.5 mg once daily in patients whose blood pressure is not adequately controlled with olmesartan monotherapy. Dose can be titrated up to 40 /25 mg if necessary. The recommended starting dose of BENICAR HCT is 20/12.5 mg once daily in patients whose blood pressure is not adequately controlled with HCT monotherapy or who experience dose-limiting adverse reactions with hydrochlorothiazide.
Read more of this section
Dose can be titrated up to 40 /25 mg if necessary. Patients titrated to the individual components (olmesartan and hydrochlorothiazide) may instead receive the corresponding dose of BENICAR HCT. Recommended starting dose in patients not adequately controlled with olmesartan monotherapy, 40/12.5 mg (2) Recommended starting dose in patients not adequately controlled with hydrochlorothiazide monotherapy, 20/12.5 mg (2) Adjust dose after 2 to 4 weeks, as needed, to a maximum of 40 mg / 25 mg olmesartan / hydrochlorothiazide (2)
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. Read the full label on DailyMed →
Olmesartan medoxomil and hydrochlorothiazide in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity, and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.
Read more of this section
When pregnancy is detected, discontinue BENICAR HCT as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intraamniotic environment. If oligohydramnios is observed, discontinue BENICAR HCT, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to BENICAR HCT for hypotension, oliguria, and hyperkalemia [see Use in Specific Populations (8.4)].
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. Read the full label on DailyMed →
Olmesartan medoxomil and hydrochlorothiazide and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
It is not known whether olmesartan is excreted in human milk, but olmesartan is secreted at low concentration in the milk of lactating rats. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue BENICAR HCT, taking into account the importance of the drug to the mother.
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. Read the full label on DailyMed →
When Olmesartan medoxomil and hydrochlorothiazide should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
BENICAR HCT is contraindicated: In patients with hypersensitivity to any component of BENICAR HCT [see Adverse Reactions (6.1, 6.2)] In patients with anuria [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)] For coadministration with aliskiren in patients with diabetes [s ee Drug Interactions (7.4)]. Hypersensitivity to any component of BENICAR HCT (4) Anuria (4) Do not co-administer aliskiren with BENICAR HCT in patients with diabetes. (4)
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. Read the full label on DailyMed →
Olmesartan medoxomil and hydrochlorothiazide overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Olmesartan medoxomil Limited data are available related to overdosage of olmesartan medoxomil in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurs. If symptomatic hypotension should occur, supportive treatment should be initiated. The dialyzability of olmesartan is unknown.
Read more of this section
No lethality was observed in acute toxicity studies in mice and rats given single oral doses up to 2000 mg/kg olmesartan medoxomil. The minimum lethal oral dose of olmesartan medoxomil in dogs was greater than 1500 mg/kg. Hydrochlorothiazide The most common signs and symptoms of hydrochlorothiazide overdose observed in humans are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD 50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.
— FDA label: Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet |
|---|---|
| Route | Oral |
| Prescription products | 81 in the FDA NDC Directory |
| Brand names | Benicar Hct |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| hydrochlorothiazide 12.5 mg · olmesartan medoxomil 20 mg tablet | Generic | $0.1639 per tablet |
| hydrochlorothiazide 12.5 mg · olmesartan medoxomil 20 mg tablet, film coated | Generic | $0.1639 per tablet |
| hydrochlorothiazide 12.5 mg · olmesartan medoxomil 40 mg tablet | Generic | $0.2088 per tablet |
| hydrochlorothiazide 12.5 mg · olmesartan medoxomil 40 mg tablet, film coated | Generic | $0.2088 per tablet |
| hydrochlorothiazide 12.5 mg · olmesartan medoxomil 40 mg tablet, film coated | Brand: Benicar HCT | $17.20 per tablet |
| hydrochlorothiazide 25 mg · olmesartan medoxomil 40 mg tablet | Generic | $0.2055 per tablet |
| hydrochlorothiazide 25 mg · olmesartan medoxomil 40 mg tablet, film coated | Generic | $0.2055 per tablet |
NADAC list of November 11, 2026; these prices took effect between July 1, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions10 products
- Bryant Ranch Prepack9 products
- Cosette Pharmaceuticals, Inc.6 products
- AvKARE6 products
- Remedyrepack Inc.5 products
- Novadoz Pharmaceuticals LLC3 products
- Golden State Medical Supply, Inc.3 products
- Solco Healthcare US, LLC3 products
- Umedica Laboratories USA Inc.3 products
- Macleods Pharmaceuticals Limited3 products
- ScieGen Pharmaceuticals, Inc.3 products
- Ascend Laboratories, LLC3 products
- Lifestar Pharma LLC3 products
- Accord Healthcare Inc.3 products
- Camber Pharmaceuticals, Inc.3 products
- Micro Labs Limited3 products
- Aurobindo Pharma Limited3 products
- Alembic Pharmaceuticals Limited3 products
- NorthStar RxLLC3 products
- Alembic Pharmaceuticals Inc.3 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021532 BENICAR HCT | Cosette | June 5, 2003 | 18, latest April 10, 2025 2025: Labeling · 2020: Labeling · 2016: Manufacturing (CMC) |
Generic approvals (11)
- ANDA204233Alembic · April 24, 2017
- ANDA205391Aurobindo Pharma · April 24, 2017
- ANDA207804Prinston · April 24, 2017
- ANDA209281Accord Hlthcare · February 7, 2019
- ANDA208847Pharmazone · September 17, 2019
- ANDA204801Macleods Pharms · June 1, 2023
- ANDA207037Alkem Labs Ltd · July 11, 2024
- ANDA209199Hetero Labs Ltd V · July 25, 2025
- ANDA217398Msn · September 26, 2025
- ANDA208465Sciegen Pharms · March 31, 2026
- ANDA206371Micro Labs · April 13, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Benicar HCTBrand page: products, maker and price
- Heart failureCondition named on the label: hospitals that treat it
- High blood pressureCondition named on the label: hospitals that treat it
- StrokeCondition named on the label: hospitals that treat it
- A-S Medication SolutionsMaker or distributor
- Bryant Ranch PrepackMaker or distributor
- Cosette Pharmaceuticals, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Olmesartan Medoxomil-Hydrochlorothiazide, AvKARE, effective July 14, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →